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OBJECTIVES:We evaluated treatment patterns, hypoglycemic events, glycemic con-
trol and medical costs for patients 60y with type 2 diabetes mellitus (T2DM) newly
initiating treatment on exenatide BID (ExBID) or insulin glargine (IG).METHODS:Med-
ical, pharmacy and lab data for commercial and Medicare Advantage enrollees were
obtained fromadministrative claims froma large, national health plan. Subjectswere
identified fromMay2005 toDec2008with6-mobaselineand12-mo follow-upperiods.
Subjects with any insulin treatment during baseline were excluded. Propensity score
(PS) matching (1:1) of ExBID and IG subjects was used to create balanced cohorts.
Logistic regression models were used to analyze medication adherence (Medication
Possession Ratio (MPR) 80%), therapy persistence (gap of 60 days in treatment 
discontinuation), any acute hypoglycemic event, and glycemic control (follow-upA1C
levels of7%). RESULTS: The finalmatched study sample included 3,263 subjects per
cohort; average age was 65y (SD 4.9); 48% were female; 83% were enrolled in a com-
mercial health plan. In the follow-up period, ExBID patients experienced significantly
fewer hypoglycemic events compared to IG patients (15 vs. 40, p0.001). Subjects in
theExBIDcohortwerealsomore likely toobtainanMPR80% (OddsRatio (OR)1.93,
CL1.72-2.17), less likely todiscontinue therapy (OR0.28,CL0.25-0.31) and less likely to
have any acute hypoglycemic event (OR0.48, CL 0.26-0.88) during the follow-up pe-
riod. For those with valid A1C levels in both baseline and follow-up periods (N669;
ExBID359, IG310), ExBID subjects were more likely to achieve A1C 7% (OR1.62,
CL 1.11-2.35) compared to IG subjects. Associated medical costs were similar for both
groups. Results were comparable for patients  65y. CONCLUSIONS: Older ExBID
subjects were more likely to adhere to therapy and achieve A1C 7% and less likely
to discontinue therapy or experience any acute hypoglycemic event than older IG
subjects.
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OBJECTIVES: The Total Illness Burden Index (TIBI) is a well-validated, patient-
reported measure of the presence and severity of medical conditions comorbid to
an index condition and is an important component of the Potential for Benefit
Conceptual Model, shown to predict response to treatment in diabetes. The objec-
tive of this research was to determine the one-year stability of the TIBI.METHODS:
We identified patients with type 2 diabetes enrolled in the Reducing Racial Dispar-
ities in Diabetes Coached Care (R2D2C2) studywho had completed the 47-item TIBI
at baseline and one year follow-up, and whose antihyperglycemic medication reg-
imen had not changed (n364). For this sample, we estimated standard error of
measurement (SEM) for the TIBI and compared changes in TIBI scores using paired
t-tests and limits of agreement. RESULTS: SEM for the TIBI-47 was 0.90. Scores for
baseline and follow-up were 3.52 and 2.88 respectively (range  0-13), mean im-
provement  0.64, within the SEM. 82.2% of respondents had a change in the TIBI
score of 3 points. Minor improvements ( 5% of scale range) were observed in
transient symptoms (e.g. fluwith cough, shortness of breath, etc.) versus diagnoses
(e.g. congestive heart failure, stroke, etc.). All changes in symptoms were within
SEM for respective TIBI subdimensions. CONCLUSIONS: TIBI scores appeared to be
highly stable for this study sample over the one-year observation period. Small
changes observed in symptom severity itemsmay be due to effective clinical man-
agement. Further research is needed to distinguish observed differences due to
treatment response from measurement error.
PDB3
LONG-TERM ANTIPROTEINURIC EFFECT OF ALISKIREN IN DIABETIC PATIENTS
WITH PERSISTENT ALBUMINURIA DESPITE CHRONIC ACEI OR ARB TREATMENT
Huang W1, Mersy JH1, Levin P2
1Greater Baltimore Medical Center, Baltimore, MD, USA, 2Bay West Endocrinology Associates,
Baltimore, MD, USA
OBJECTIVES: Studies showed dual blockade of renin-angiotensin-aldosterone sys-
tem with ACEI and ARB had produced little gain with significant side effects in
proteinuric patients. Here we evaluated the real-world effectiveness of long-term
antiproteinuric effects of a novel dual blockade with the direct renin inhibitor
aliskiren addition on chronic ACEI or ARB treatment in diabetic patients with per-
sistent albuminuria. METHODS: We retrospectively collected data from the elec-
tronic database of Baywest Endocrinology Associates. Aliskiren150- 300mg daily
was added on chronic ACEI/ARB treatment (mean known duration 6 years). The
Cockroft-Gault formula was used to estimate the glomerular filtration rate (eGFR).
TheWilcoxon Signed Ranks test andKendall’s tau-b correlation analysiswere used
to calculate statistical significance. p0.05 was considered significant. RESULTS:
Twenty-four (mean age 64 years) patients were selected, with a mean observation
time 15 months before and 20 months after aliskiren addition. There was a signif-
icant rise in urinary albumin-to-creatinine ratio (Ualb/Cr) [unit: mg/g, 146.3 (16.1-
1978.7) vs. 51.0 (34-1170.3)] and SBP (unit: mmHg, 158  19 vs. 142 21) in these
patients at baseline (i.e., whenAliskirenwas added)when comparedwith that of 15
months before (p0.05). And therewas a significant decline in albuminuria and SBP
20 months after aliskiren addition: reduced median Ualb/Cr was 73.3%, reduced
mean SBP was 24 mmHg (p0.001). However, reduction in Ualb/Cr was not related
to reduction in SBP (p0.05). No changes were found in the DBP, HbA1c, serum
creatinine and eGFR. A small increment of serum potassium levels was detected
after aliskiren addition( unit: mmol/L, 4.50.6 vs 4.4  0.4 mmol/L at baseline,
p0.05 ). During the study, no adverse events, including symptoms of hyperkale-
mia and hypotension, were documented. CONCLUSIONS: Aliskiren addition to
ACEI/ARB may have extra antiproteinuric effects that might be independent on BP
reduction and held without rebound as long as 1.5 year follow-up.
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OBJECTIVES: Exenatide once-weekly (ExQW) is a GLP-1 receptor agonist that im-
proves glycemia in patients with type 2 diabetes (T2DM) while eliciting potential
weight loss and improvement in cardiovascular risk factors (blood pressure (BP) and
plasma lipids). In published trials, ExQW resulted in superior reduction in A1C com-
pared tomaximumdaily doses of sitagliptin andpioglitazone (Pio) onmetformin (Met)
background, and to titrated insulin glargine. METHODS: We used the Archimedes
Model, a validated, clinically detailed model of physiology, disease, and healthcare
delivery, to explore potential long-termExQWbenefits and costs.We simulated 20y of
treatment in a virtual population (n19,885) based on individuals with T2DM drawn
from NHANES who were on Met/sulfonylureas (mean age 59y, BMI 33kg/m2, wt
93kg, duration T2DM 9y, baseline A1C 8%). The effects of three treatment regimens
were modeled at simulation start: 1) advancement to insulin at A1C 8% (treat to
target A1C7%), 2) addition of Pio, and 3) addition of ExQW. ExQW’s effect on A1C,
weight, BP, and lipidswas derived from four phase 3 ExQW trials. Medical costs (inpa-
tient, outpatient, ambulatory, treatments) were derived from the Medicare Current
Beneficiary Survey, Medicare Part D data, drugstore.com, and published literature.
Since ExQW is investigational, antidiabetic therapy costswere excluded.RESULTS:At
20y, final mean A1C was 7% in all arms. Compared to insulin and Pio, respectively,
ExQWwas associatedwith relative reductions in finalmeanweight (5% vs. both com-
parators), incidence of first Major Adverse Cardiovascular Event (8.2% and 3.3%), and
CHF (5.1% and 15.0%). All arms showed comparable benefit in controlling neuropathy,
but ExQW showed significantly greater reductions in renal complications. As early as
5y, ExQW demonstrated total cost-savings of $545 and $379 per life-year vs. insulin
and Pio, respectively. CONCLUSIONS: These simulations suggest that the benefits of
ExQWmay translate into clinically and economically meaningful reductions in long-
term outcomes.
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OBJECTIVES: To examine the impact of antidiabetic-induced hypoglycemia on
clinical outcomes and resource utilization among T2DM patients in the Veterans
Affairs.METHODS:This retrospective cohort study used electronicmedical records
between 01/01/2004 and 09/01/2010 from the Veterans Integrated Service Network
(VISN) 16 datawarehouse. Patientswere required to have at least 2 records of T2DM
ICD-9-CM diagnosis (250.xx except for 250.x1 and 250.x3). The first dispense date of
a new antidibetic agent (index drug) were defined as the index date. No hypoglycemia
diagnosis was allowed during the one-year pre-index period. The hypoglycemia co-
hort and control cohort were defined by ICD-9-CM diagnosis of hypoglycemia (250.8,
251.0, 251.1 and251.2)within the index-treatmentperiod andnohypoglycemiaduring
the one-year post-index period, respectively. Clinical outcomes included hemoglobin
A1c, cardiovascular diseases (CVD) andmicro-vascular complications. Resource utili-
zation included hospitalizations and emergency room (ER) visits. Clinical outcomes
were compared by Cox regression models, controlling for age, race, index drug, renal
functions, andbaseline variables: A1c, Charlson comorbidity index (CCI), and resource
utilization. RESULTS: Among 42,437 T2DM patients, 369 patients of the hypoglyce-
mia cohort and 42,068 patients of the control cohort differed in racial and marital
status, baseline CCI and resource utilization. The hypoglycemia cohort was more
likely to receive insulin/sulfonylurea as index drug. The post-index A1c was nu-
merically higher in the hypoglycemia cohort than control cohort (10.12 vs 9.87, p
0.0602). The hypoglycemia cohortwasmore likely to develop CVD (HR1.32, 95%CI:
1.13-1.54) and 40%more likely to developmicro-vascular complications, compared
with the control cohort. Risks of hospitalization and ER visit were higher for the
hypoglycemia cohort than control cohort (18.2% vs. 9.2%, 32.3% vs. 20.7%, both
p-values  .0001, respectively). CONCLUSIONS: Patients with hypoglycemia may
lead toworse clinical outcomes andhigher risks of hospitalization and ER visit than
those without.
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